In this article, we discuss the 5 micro-cap stocks to buy according to Cathie Wood. If you want our detailed analysis of Cathie Wood’s investment philosophy and hedge fund performance, go directly to the 10 Micro-Cap Stocks to Buy According to Cathie Wood.
5. Evogene Ltd. (NASDAQ:EVGN)
ARK Investment Management’s Stake Value: $10,653,000
Percentage of ARK Investment Management’s 13F Portfolio: 0.02%
Number of Hedge Fund Holders: 6
Market Capitalization: $84.387 million
Roth Capital analyst Brian Wright initiated coverage of Evogene Ltd. (NASDAQ:EVGN) on October 8 with a Buy rating and a $7 price target, citing the company’s robust pipeline of pre-clinical micro biome-based drug candidates in its biotech subsidiary and Evogene Ltd. (NASDAQ:EVGN) being on the cusp of commercialization of its first products in ag-biologics and cannabis.
A computational biology company engaged in product discovery and development in the life sciences industries like human health and agriculture, Evogene Ltd. (NASDAQ:EVGN) applies its technology platform, Computational Predictive Biology (CPB), leveraging big data and AI to guide the development of life sciences products by studying microbes, small molecules, and genetic elements.
Cathie Wood owns more than 4 million Evogene Ltd. (NASDAQ:EVGN) shares worth $10.65 million in the third quarter, representing 0.02% of her total 13F securities for Q3.
A total of 6 hedge funds monitored by Insider Monkey at the end of September were long Evogene Ltd. (NASDAQ:EVGN), with stakes valued at $13 million. Jim Simons’ Renaissance Technologies increased its position in Evogene Ltd. (NASDAQ:EVGN) by 155% in the third quarter, holding a $700,000 stake in the company.
On November 17, Evogene Ltd. (NASDAQ:EVGN) reported Q3 earnings, posting a loss per share of $0.19, missing estimates by $0.01. The quarterly revenue of $151,000 exceeded estimates by $39,000.
4. Conformis, Inc. (NASDAQ:CFMS)
ARK Investment Management’s Stake Value: $19,354,000
Percentage of ARK Investment Management’s 13F Portfolio: 0.04%
Number of Hedge Fund Holders: 8
Market Capitalization: $148.895 million
In the earnings results for the quarter ending September, posted on November 3, Conformis, Inc. (NASDAQ:CFMS) announced a loss per share of $0.07, missing estimates by $0.01. The $14.25 million revenue was down 11.59% year-over-year, but exceeded estimates by $108,000.
Conformis, Inc. (NASDAQ:CFMS) is a surgical and medical instrument manufacturing company from Massachusetts, specializing in customized hip and knee replacements.
Conformis, Inc. (NASDAQ:CFMS) is a new arrival in Cathie Wood’s Q3 portfolio, with ARK Investment Management holding 14.55 million shares of the company, worth $19.35 million. Conformis, Inc. (NASDAQ:CFMS) is one of the top micro-cap stocks to buy according to Cathie Wood, representing 0.04% of her total Q3 investments.
John Overdeck and David Siegel’s Two Sigma Advisors holds one of the leading positions in Conformis, Inc. (NASDAQ:CFMS) as of September this year, with 2.87 million shares worth $3.8 million. Overall, 8 hedge funds in the database of Insider Monkey were bullish on Conformis, Inc. (NASDAQ:CFMS) in the third quarter, down from 9 funds in the prior quarter.
3. Dynamics Special Purpose Corp. (NASDAQ:DYNS)
ARK Investment Management’s Stake Value: $23,132,000
Percentage of ARK Investment Management’s 13F Portfolio: 0.05%
Number of Hedge Fund Holders: N/A
Market Capitalization: $292.003 million
Dynamics Special Purpose Corp. (NASDAQ:DYNS) is a blank check company that was incorporated in March 2021, created for the purpose of carrying out multiple business combinations including mergers, share exchange, asset acquisitions, and corporate restructuring.
Cathie Wood, via ARK Investment Management, holds 3.32 million shares in Dynamics Special Purpose Corp. (NASDAQ:DYNS), worth $23.1 million at the end of September, representing 0.05% of the fund’s total Q3 portfolio.
Billionaire Daniel Sundheim’s D1 Capital Partners is one of the most prominent Dynamics Special Purpose Corp. (NASDAQ:DYNS) stakeholders from the third quarter, with 1.95 million shares worth $19.3 million.
2. AquaBounty Technologies, Inc. (NASDAQ:AQB)
ARK Investment Management’s Stake Value: $25,221,000
Percentage of ARK Investment Management’s 13F Portfolio: 0.06%
Number of Hedge Fund Holders: 6
Market Capitalization: $170.107 million
AquaBounty Technologies, Inc. (NASDAQ:AQB), one of the top micro-cap stocks to buy according to Cathie Wood, is a biotechnology company from Massachusetts known for its research and development of genetically modified fish. AquaBounty Technologies, Inc. (NASDAQ:AQB) is working to create products that increase the productivity of aquaculture.
ARK Investment Management holds a $25.2 million stake in AquaBounty Technologies, Inc. (NASDAQ:AQB) as of Q3 2021, which accounts for 0.06% of the hedge fund’s total investments for the quarter.
AquaBounty Technologies, Inc. (NASDAQ:AQB), on November 4, announced its Q3 results. The company posted a loss per share of $0.10, missing estimates by $0.03. The $455,400 revenue for the quarter also missed estimates by $242,100.
On November 9, H.C. Wainwright analyst Kevin Dede upgraded AquaBounty Technologies, Inc. (NASDAQ:AQB) to Buy from Neutral with a $4.50 price target, stating that the company addressed many questions and unknowns when reporting Q3 results.
At the end of the third quarter, 6 hedge funds reported owning stakes in AquaBounty Technologies, Inc. (NASDAQ:AQB), worth $27.5 million. This is compared to 4 funds being bullish on the stock in the preceding quarter, with the total stakes amounting to $41.2 million.
1. Surface Oncology, Inc. (NASDAQ:SURF)
ARK Investment Management’s Stake Value: $34,961,000
Percentage of ARK Investment Management’s 13F Portfolio: 0.08%
Number of Hedge Fund Holders: 12
Market Capitalization: $251.898 million
Surface Oncology, Inc. (NASDAQ:SURF) is the top micro-cap stock in Cathie Wood’s 13F portfolio for the third quarter, with Wood owning 4.61 million Surface Oncology, Inc. (NASDAQ:SURF) shares, worth $34.96 million, representing 0.08% of her total investments.
Surface Oncology, Inc. (NASDAQ:SURF) is a company focused on developing next generation immunotherapies targeting the immune-suppressive tumor microenvironment to combat cancer.
The third quarter earnings were published on November 4 by Surface Oncology, Inc. (NASDAQ:SURF), with the company reporting a loss per share of $0.44, missing estimates by $0.04.
In Q3 2021, 12 hedge funds reported owning stakes in Surface Oncology, Inc. (NASDAQ:SURF), worth $66.4 million. This is an increase as compared to 10 funds holding stakes in the company valued at $58.78 million in the preceding quarter.
Ken Griffin’s Citadel Investment Group is one of the biggest stakeholders of Surface Oncology, Inc. (NASDAQ:SURF), with 1.45 million shares worth more than $11 million.
You can also take a look at Echo Street Capital Management: Greg Poole’s Top 10 Stock Picks and 10 Dividend Stocks With the Potential to Grow.
